Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | L505H |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | BRAF L505H lies within the protein kinase domain of the Braf protein (UniProt.org). L505H confers a gain of function to the Braf protein resulting in MEK/ERK activation and oncogenic transformation in cultured cells, and is associated with resistance to RAF inhibitors (PMID: 24283590). |
Associated Drug Resistance | Y |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF L505H |
Transcript | NM_004333.6 |
gDNA | chr7:g.140777994A>T |
cDNA | c.1514T>A |
Protein | p.L505H |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001378468.1 | chr7:g.140777994A>T | c.1514T>A | p.L505H | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140777994A>T | c.1514T>A | p.L505H | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140777994A>T | c.1514T>A | p.L505H | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140777994A>T | c.1514T>A | p.L505H | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140777994A>T | c.1514T>A | p.L505H | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140777994A>T | c.1514T>A | p.L505H | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140777994A>T | c.1514T>A | p.L505H | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140777994A>T | c.1514T>A | p.L505H | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140777994A>T | c.1514T>A | p.L505H | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF L505H | Advanced Solid Tumor | predicted - resistant | Dabrafenib | Preclinical - Biochemical | Actionable | In a preclinical study, cells expressing BRAF L505H were resistant to treatment with Tafinlar (dabrafenib) in culture (PMID: 34108213). | 34108213 |
BRAF L505H | melanoma | resistant | Vemurafenib | Preclinical | Actionable | In a preclinical study, melanoma cells expressing BRAF L505H were resistant to Zelboraf (vemurafenib) (PMID: 24283590). | 24283590 |
BRAF L505H | Advanced Solid Tumor | predicted - resistant | Vemurafenib | Preclinical - Biochemical | Actionable | In a preclinical study, cells expressing BRAF L505H were resistant to treatment with Zelboraf (vemurafenib) in culture (PMID: 34108213). | 34108213 |
BRAF L505H | Advanced Solid Tumor | predicted - resistant | PLX8394 | Preclinical - Biochemical | Actionable | In a preclinical study, cells expressing BRAF L505H were resistant to treatment with PLX8394 in culture (PMID: 34108213). | 34108213 |
BRAF L505H | Advanced Solid Tumor | predicted - resistant | LY3009120 | Preclinical - Biochemical | Actionable | In a preclinical study, cells expressing BRAF L505H were resistant to treatment with LY3009120 in culture (PMID: 34108213). | 34108213 |